Dyne Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Dyne Therapeutics, Inc. (DYN) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$299.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-07-29
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$178.56M.
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$120.85M.
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$111.95M.
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$108.04M.
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$446.21M.
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$317.42M.
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$235.94M.
- Dyne Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$168.10M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$178.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$299.41M 10-Q · filed 2026-07-29 | -$411.37M derived: sum of 3 quarters · filed 2026-07-29 | -$519.40M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$120.85M 10-Q · filed 2026-05-11 | -$232.81M derived: sum of 2 quarters · filed 2026-05-11 | -$340.85M derived: sum of 3 quarters · filed 2026-05-11 | -$451.71M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$111.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$220.00M derived: sum of 2 quarters · filed 2026-03-02 | -$330.85M derived: sum of 3 quarters · filed 2026-07-29 | -$446.21M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$108.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$218.90M derived: sum of 2 quarters · filed 2026-07-29 | -$334.26M 10-Q · filed 2025-11-05 | -$423.80M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$110.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$226.22M 10-Q · filed 2026-07-29 | -$315.76M derived: sum of 3 quarters · filed 2026-07-29 | -$412.89M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$115.36M 10-Q · filed 2026-05-11 | -$204.90M derived: sum of 2 quarters · filed 2026-05-11 | -$302.03M derived: sum of 3 quarters · filed 2026-05-11 | -$367.13M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$89.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$186.67M derived: sum of 2 quarters · filed 2026-03-02 | -$251.77M derived: sum of 3 quarters · filed 2026-03-02 | -$317.42M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$97.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$162.23M derived: sum of 2 quarters · filed 2025-11-05 | -$227.88M 10-Q · filed 2025-11-05 | -$294.51M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$65.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | -$130.75M 10-Q · filed 2025-07-28 | -$197.39M derived: sum of 3 quarters · filed 2026-03-02 | -$257.60M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$65.65M 10-Q · filed 2025-05-08 | -$132.29M derived: sum of 2 quarters · filed 2026-03-02 | -$192.50M derived: sum of 3 quarters · filed 2026-03-02 | -$257.40M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$66.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$126.85M derived: sum of 2 quarters · filed 2026-03-02 | -$191.75M derived: sum of 3 quarters · filed 2026-03-02 | -$235.94M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$60.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$125.11M derived: sum of 2 quarters · filed 2024-11-12 | -$169.30M 10-Q · filed 2024-11-12 | -$208.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$64.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$109.09M 10-Q · filed 2024-08-12 | -$147.92M derived: sum of 3 quarters · filed 2025-02-27 | -$189.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$44.19M 10-Q · filed 2024-05-02 | -$83.01M derived: sum of 2 quarters · filed 2025-02-27 | -$124.40M derived: sum of 3 quarters · filed 2025-02-27 | -$176.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$38.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$80.21M derived: sum of 2 quarters · filed 2025-02-27 | -$132.52M derived: sum of 3 quarters · filed 2025-02-27 | -$168.10M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$41.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | -$93.69M derived: sum of 2 quarters · filed 2023-10-30 | -$129.27M 10-Q · filed 2023-10-30 | -$181.06M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | -$52.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$87.89M 10-Q · filed 2023-08-03 | -$139.67M derived: sum of 3 quarters · filed 2023-08-03 | -$182.25M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$35.58M 10-Q · filed 2023-05-11 | -$87.37M derived: sum of 2 quarters · filed 2023-05-11 | -$129.95M derived: sum of 3 quarters · filed 2023-05-11 | -$159.91M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$51.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$94.37M derived: sum of 2 quarters · filed 2023-03-02 | -$124.32M derived: sum of 3 quarters · filed 2023-03-02 | -$149.29M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$42.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$72.54M derived: sum of 2 quarters · filed 2022-11-03 | -$97.50M 10-Q · filed 2022-11-03 | -$126.15M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$29.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$54.92M 10-Q · filed 2022-08-04 | -$83.57M derived: sum of 3 quarters · filed 2022-08-04 | -$97.49M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$24.97M 10-Q · filed 2022-05-02 | -$53.62M derived: sum of 2 quarters · filed 2022-05-02 | -$67.54M derived: sum of 3 quarters · filed 2022-05-02 | -$76.52M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | -$28.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$42.57M derived: sum of 2 quarters · filed 2022-03-10 | -$51.55M derived: sum of 3 quarters · filed 2022-03-10 | -$59.44M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$13.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$22.90M derived: sum of 2 quarters · filed 2021-11-04 | -$30.79M 10-Q · filed 2021-11-04 | -$36.19M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$8.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$16.87M 10-Q · filed 2021-08-05 | -$22.27M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$7.89M 10-Q · filed 2021-05-06 | -$13.29M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$14.86M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | -$9.46M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |